Phase IIA Double-Masked Randomized Sham-Controlled Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Subjects With Acute Primary Angle-Closure Glaucoma (APACG)
Phase of Trial: Phase II
Latest Information Update: 11 Apr 2017
Price : $35 *
At a glance
- Drugs QPI 1007 (Primary)
- Indications Angle-closure glaucoma
- Focus Adverse reactions
- Sponsors Quark Pharmaceuticals
- 15 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 24 Mar 2015 Planned End Date changed from 1 Dec 2015 to 1 Jul 2015, as reported by ClinicalTrials.gov.
- 24 Mar 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.